ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
1. An oligonucleotide having the nucleotide sequence as shown in SEQ ID NO: 75 or 77 in the SEQUENCE LISTING, or a pharmacologically acceptable salt thereof, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
2. The oligonucleotide of claim 1 , wherein the oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 75 in the SEQUENCE LISTING, or a pharmacologically acceptable salt thereof, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
3. The oligonucleotide of claim 1 , wherein the oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 77 in the SEQUENCE LISTING, or a pharmacologically acceptable salt thereof, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
4. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one of sugar constituting the oligonucleotide is modified, the sugar constituting the oligonucleotide is D-ribofuranose, and the modification of the sugar is modification of the hydroxyl group at position 2′ of D-ribofuranose.
5. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein the modification of the sugar is 2′-O-alkylation and/or 2′-O,4′-C-alkylenation of the D-ribofuranose.
6. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one of sugar constituting the oligonucleotide is modified, and said modification is selected from the group consisting of 2′-O-methylation of D-ribofuranose, 2′-O-aminoethylation of D-ribofuranose, 2′-O-propylation of D-ribofuranose, 2′-O-allylation of D-ribofuranose, 2′-O-methoxyethylation of D-ribofuranose, 2′-O-butylation of D-ribofuranose, 2′-O-pentylation of D-ribofuranose, 2′-O-propargylation of D-ribofuranose, 2′-O,4′-C-ethylenation of D-ribofuranose, 2′-O,4′-C-methylenation of D-ribofuranose, 2′-O,4′-C-propylenation of D-ribofuranose, 2′-O,4′-C-tetramethylation of D-ribofuranose, 2′-O,4′-C-pentamethylation of D-ribofuranose, 3′-deoxy-3′-amino-2′-deoxy-D-ribofuranose, and 3′-deoxy-3′-amino-2′-deoxy-2′-fluoro-D-ribofuranose.
7. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one of phosphate constituting the oligonucleotide is modified and the modification of the phosphate is thioation of the phosphate group.
8. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one sugar constituting the oligonucleotide is modified and at least one phosphate constituting the oligonucleotide is modified.
9. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one sugar constituting the oligonucleotide is modified.
10. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one phosphate constituting the oligonucleotide is modified.
11. An oligonucleotide having the nucleotide sequence as shown in SEQ ID NO: 23, 214, or 215 in the SEQUENCE LISTING, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated, wherein:
the oligonucleotide of SEQ ID NO: 23 has the structure of AO90 or AO91:
AO90: HO-C e2p -U mp -G mp -C e2p -U mp -U mp -C e2p -C e2p -U mp -C e2p -C e2p -A mp -A mp -C e2p -C e2p -CH 2 CH 2 OH
AO91: HO-C e2s -U ms -G ms -C e2s -U ms -U ms -C e2s -C e2s -U ms -C e2s -C e2s -A ms -A ms -C e2s -C e2s -CH 2 CH 2 OH
the oligonucleotide of SEQ ID NO: 214 has the structure of AO27, AO89, AO92, or AO93:
AO27: HO-C e2p -T e2p -G e2p -C e2p -T e2p -U mp -C mp -C mp -U mp -C mp -C e2p -A e2p -A e2p -C e2p -C e2p -CH 2 CH 2 OH
AO89: HO-C e2s -T e2s -G e2s -C e2s -T e2s -U ms -C ms -C ms -U ms -C ms -C e2s -A e2s -A e2s -C e2s -C e2s -CH 2 CH 2 OH
AO92: HO-C e2p -T e2p -G mp -C e2p -T e2p -U mp -C mp -C e2p -U mp -C mp -C e2p -A mp -A mp -C e2p -C e2p -CH 2 CH 2 OH
AO93: HO-C e2s -T e2s -G ms -C e2s -T e2s -U ms -C ms -C e2s -U ms -C ms -C e2s -A ms -A ms -C e2s -C e2s -CH 2 CH 2 OH
the oligonucleotide of SEQ ID NO: 215 has the structure of AO28:
AO28: HO-G e2p -T e2p -T e2p -A e2p -T e2p -C mp -U mp -G mp -C mp -U mp -U mp -C mp -C mp -U mp -C mp -C e2p -A e2p -A e2p -C e2p -C e2p -CH 2 CH 2 OH
wherein A e2p , G e2p , C e2p , T e2p , A mp , G mp , C mp , U mp , A e2s , G e2s , C e2s , T e2s , A ms , G ms , C ms , and U ms have the following structures:
12. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO90, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.
13. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO91, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.
14. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO27, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.
15. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO89, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.
16. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO92, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.
17. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO93, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.
18. The oligonucleotide of claim 11 , wherein the oligonucleotide has the nucleotide sequence AO28, or a pharmacologically acceptable salt thereof, wherein at least one D-ribofuranose constituting the oligonucleotide is 2′-O,4′-C-ethylenated.